⌕
Liminatus Pharma · LIMN · Nasdaq
Tenet 6 · Weak
Compare
$2.81+4.85%At closeTenet 6 · Weak
$2.81+0.13 (+4.85%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Liminatus Pharma (LIMN) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼187.8%
−10.2
FY21→FY25CAGR —
Free cash flow ($M)▼587.5%
−10.0
FY21→FY25CAGR —
Diluted EPS▼115.0%
−0.43
buyback-liftedCAGR —
What the receipts whisper · what a headline number hides
Share count
−31.1%

34.5mn → 23.8mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit0.0R&D−3.0SG&A−3.0Op income−7.2Tax & other−10.2Net income

Margin trend · direction beats level
00000%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.4908, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
1,000.00.02,685.33,757.01,853.03,802.0——
Selling, general & admin
3,065.22,967.8644.61,062.0856.0197.0▲360.4%+97.0%
Total operating expenses
4,065.22,967.83,330.02,586.22,709.02,534.3▼10.9%+4.0%
Operating incomefeeds ROC rank
−4,065.2−2,967.8−3,330.0−2,586.2−2,709.0−2,534.3▲10.9%—
Other income, net
−8,458.1−7,238.7−216.41,394.0−219.06,903.9——
Pretax income
−12,523.3−10,206.5−3,546.3−1,192.2−2,928.04,369.7▼187.8%—
Income tax
———34.00.00.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−12,523.3−10,206.5−3,546.3−1,226.2−2,928.04,369.7▼187.8%—
Per share
Diluted EPSbuyback-sensitive
—−0.43−0.20−0.15−0.080.13▼115.0%—
Diluted shares (mn)
—23.7517.508.0134.4334.50▲35.7%−8.9%
Margins
† TTM = trailing four quarters through 2026-06-30.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-31 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.